HXN-1002

N/A

Report date: 2025/04/21 14:23:10

First In Class

Base Information

Drug NameHXN-1002

Drug Alias NameHXN-1002

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionTumor necrosis factor superfamily member 15 inhibitorsIntegrin alpha-4/beta-7 antagonists

TargetsTumor necrosis factor superfamily member 15Integrin alpha-4/beta-7

Therapy Area/IndicationsInflammatory Bowel Diseases

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesEarendil Labs Helixon Ltd

China Registration ClassN/A

Develop Information

Active CompaniesHelixon Ltd Sanofi

Inactive CompaniesN/A

Active IndicationsInflammatory Bowel Diseases

Inactive IndicationsN/A

Other Information

ATC CodeN/A